Clinical Trials Logo

Clinical Trial Summary

Background: Over the past few decades, fructose is increasingly being used as a sweetener/ additive in a variety of foods. Incomplete absorption of fructose has been implicated as a cause of gastrointestinal symptoms. In tertiary care centers, the prevalence of fructose malabsorption in subjects with unexplained GI symptoms is thought to be between 11-50%, when assessed with breath tests following administration of 25 grams of fructose in a 10% solution. Restriction of dietary fructose has been shown to improve symptoms in these patients to an extent. Currently, there are no therapeutic agents that improve intestinal fructose absorption and thereby decrease symptoms. Studies in the pediatric population have shown that fructose absorption in the small intestine is increased in the presence of glucose or amino acids, especially alanine. Objective: The investigators' objective is to assess whether co-administration of an oral solution of L-alanine facilitates fructose absorption and decreases gastrointestinal (GI) symptoms associated with fructose malabsorption in subjects undergoing standard fructose breath test when compared to placebo. Methods and analysis: The investigators propose a randomized, double-blind study in 40 subjects with known fructose intolerance. After an overnight fast, each subject will receive an oral solution of 12.5 grams of alanine in 125cc of water or placebo. Next, the subject will receive an oral solution of 25 grams of fructose in a 10% solution. Serum, urine and breath samples will be collected at baseline and at 30-minute intervals for 4 hours. GI symptoms will also be assessed and recorded at 30 minute intervals using a standard questionnaire. Repeated measures ANOVA will be used to compare the data obtained during the study protocol with the baseline (pre-study) data. Expected outcomes: Co-administration of alanine with fructose may improve fructose absorption and decrease symptoms in subjects with fructose intolerance. Hypothesis: Ingestion of alanine along with fructose, will facilitate intestinal absorption of fructose in subjects with fructose malabsorption. Aim: To investigate the effects of co-administration of equi-molar doses of alanine on a) the absorption of fructose and b) the occurrence of GI symptoms in subjects with fructose malabsorption.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01185210
Study type Interventional
Source Augusta University
Contact Satish SC Rao, MD
Phone 319-353-6602
Email satish-rao@uiowa.edu
Status Recruiting
Phase N/A
Start date September 2007
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06044389 - Observational Study on the Safety and Efficacy of the Medical Product Fructosin.
Recruiting NCT02085889 - Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders
Recruiting NCT04022434 - Investigation of Supplemental L-alanine in the Management of Dietary Fructose Intolerance N/A
Completed NCT01705171 - Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?
Completed NCT03261856 - Clinical Utility of Breath Tests in GI